Advertisement
New Zealand markets close in 1 hour 50 minutes
  • NZX 50

    11,752.47
    +81.28 (+0.70%)
     
  • NZD/USD

    0.6133
    -0.0002 (-0.02%)
     
  • NZD/EUR

    0.5704
    -0.0000 (-0.01%)
     
  • ALL ORDS

    8,006.90
    -3.60 (-0.04%)
     
  • ASX 200

    7,764.90
    -4.80 (-0.06%)
     
  • OIL

    81.47
    -0.10 (-0.12%)
     
  • GOLD

    2,347.10
    +0.20 (+0.01%)
     
  • NASDAQ

    19,908.86
    +6.11 (+0.03%)
     
  • FTSE

    8,205.11
    +13.82 (+0.17%)
     
  • Dow Jones

    38,834.86
    +56.76 (+0.15%)
     
  • DAX

    18,067.91
    -64.06 (-0.35%)
     
  • Hang Seng

    18,387.89
    -42.50 (-0.23%)
     
  • NIKKEI 225

    38,324.10
    -246.66 (-0.64%)
     
  • NZD/JPY

    96.9120
    +0.0600 (+0.06%)
     

Pfizer (PFE) Gains But Lags Market: What You Should Know

Pfizer (PFE) closed the most recent trading day at $39.09, moving +0.51% from the previous trading session. This move lagged the S&P 500's daily gain of 0.62%. At the same time, the Dow added 0.5%, and the tech-heavy Nasdaq lost 5.66%.

Heading into today, shares of the drugmaker had gained 1.54% over the past month, outpacing the Medical sector's loss of 2.88% and lagging the S&P 500's gain of 3.44% in that time.

Wall Street will be looking for positivity from Pfizer as it approaches its next earnings report date. In that report, analysts expect Pfizer to post earnings of $0.63 per share. This would mark a year-over-year decline of 69.12%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $14.01 billion, down 49.51% from the year-ago period.

Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $3.35 per share and revenue of $68.1 billion. These totals would mark changes of -49.09% and -32.13%, respectively, from last year.

ADVERTISEMENT

Investors might also notice recent changes to analyst estimates for Pfizer. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.

Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.04% lower. Pfizer is currently sporting a Zacks Rank of #4 (Sell).

In terms of valuation, Pfizer is currently trading at a Forward P/E ratio of 11.62. This represents a discount compared to its industry's average Forward P/E of 14.65.

Meanwhile, PFE's PEG ratio is currently 1.29. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. PFE's industry had an average PEG ratio of 1.66 as of yesterday's close.

The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 62, putting it in the top 25% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Pfizer Inc. (PFE) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research